Drugs / Enobosarm
Trials 15 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03264651 | Feb 2017 → Mar 2018 | breast disorder | Havah Therapeutics Pty Ltd | Completed | No outcome recorded |
| Phase 210 trials | ||||||
| Phase 2 | NCT07446998 | Mar 2026 → Oct 2027 expected | obesity disorder | Veru Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT06282458 | Apr 2024 → Apr 2025 | muscular atrophy, obesity disorder | Veru Inc. | Completed | No outcome recorded |
| Phase 2 | NCT03566290 | Jun → Sep 2018 | female stress incontinence | GTx | Withdrawn | No outcome recorded |
| Phase 2 | NCT02971761 | Jun 2017 → Oct 2020 | hormone receptor-positive breast cancer, triple-negative breast carcinoma | City of Hope Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT02746328 | Apr 2016 → Feb 2018 | estrogen-receptor positive breast cancer | GTx | Withdrawn | No outcome recorded |
| Phase 2 | NCT02658448 | Jan 2016 → Jun 2018 | female stress incontinence | GTx | Completed | No outcome recorded |
| Phase 2 | NCT02463032 | Aug 2015 → Mar 2019 | estrogen-receptor positive breast cancer | GTx | Completed | No outcome recorded |
| Phase 2 | NCT02368691 | Jun 2015 → Sep 2017 | triple-negative breast carcinoma | GTx | Terminated | No outcome recorded |
| Phase 2 | NCT01616758 | Apr 2013 → Jun 2014 | breast cancer | GTx | Terminated | No outcome recorded |
| Phase 2 | NCT00467844 | May 2007 → Sep 2008 | hypoproteinemia, hypercatabolic | GTx | Completed | No outcome recorded |
| Phase 34 trials | ||||||
| Phase 3 | NCT05065411 | Apr 2022 → Oct 2023 | breast cancer | Veru Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT04869943 | Oct 2021 → Jan 2024 | breast cancer | Veru Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT01355484 | Jul 2011 → May 2013 | muscular atrophy, non-small cell lung carcinoma | GTx | Completed | No outcome recorded |
| Phase 3 | NCT01355497 | Jul 2011 → May 2013 | muscular atrophy, non-small cell lung carcinoma | GTx | Completed | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03508648 Comparator | May → Sep 2018 | female stress incontinence | GTx | Withdrawn | No outcome recorded |
| Phase 2 | NCT03241342 Comparator | Aug 2017 → Sep 2018 | female stress incontinence | GTx | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 19 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | enobosarm | “This randomised, double-blind, placebo-controlled phase 2 trial assessed the efficacy and safety of enobosarm, a selective androgen receptor modulator, in patients with cancer.” PMID 23499390 ↗ Mar 20137“Enobosarm, a nonsteroidal SARM, is an agent in clinical development for prevention and treatment of muscle wasting in patients with cancer” PMID 27138015 ↗ Jun 2016 |
| Known as | GTx-024 | “Study drug is an opaque, white to off-white, size 5, oval Softgel capsule containing the active ingredient GTx-024.” NCT03241342 ↗ |
| Known as | MK-2866 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1738889 ↗ |
| Known as | Ostarine | ChEMBL registry synonym — accepted as the source's own label CHEMBL1738889 ↗ |
| Action | Inhibit | “Hormone therapy using enobosarm may fight breast cancer by blocking the use of androgen by the tumor cells.” NCT02971761 ↗ |
| Modality | Small molecule | “Enobosarm, a nonsteroidal SARM” PMID 27138015 ↗ Jun 2016 |
| Route | Oral | “receive once-daily oral enobosarm 1 mg, 3 mg, or placebo” PMID 23499390 ↗ Mar 2013 |
| Target | AR | “enobosarm, a selective androgen receptor modulator” PMID 23499390 ↗ Mar 2013 |